Synthesis and Functionalization of Sulfoximine-Bicyclo[1.1.0]butanes: Functionalizable, Tuneable and Cysteine-Selective Chiral Warheads

James A Bull,Zhenhao Zhong,Brad J W Hocking,Charles P. Brown,Tsz-Kan Ma,Andrew J. P. White,David J. Mann,Alan Armstrong
DOI: https://doi.org/10.26434/chemrxiv-2024-4pknv
2024-10-16
Abstract:Electrophilic covalent warheads with appropriate reactivity and selectivity are crucial to the investigation of protein function and the discovery of therapeutics. Here we report the synthesis of sulfoximine bicyclo[1.1.0]butanes (BCBs) as novel thiol reactive chiral warheads, achieved in one-pot from methylsulfoximines. Unusually the warhead can then be derivatized, keeping the BCB intact, over 3 vectors: i) sulfoximine N-modification instills a broad range of strain-release reactivity; ii) sp2-cross-coupling reactions on aryl-BCB-sulfoximines allows direct diversification, and iii) functionalization of the BCB motif itself is achieved by metalation and trapping with electrophiles. The BCB sulfoximines are shown to react selectively with cysteine including in a protein model (CDK2) under biocompatible conditions. Preliminary data indicate suitability for chemoproteomic applications, and enantioselective cysteine-labelling. The reactivity of sulfoximine BCBs with electron withdrawing groups on nitrogen is comparable to acrylamides with low to moderate reactivity.
Chemistry
What problem does this paper attempt to address?
The paper aims to address the need for covalent warheads with appropriate reactivity and selectivity in protein function research and drug discovery. Specifically, the paper introduces a novel method for the synthesis and functionalization of sulfoximine bicyclo[1.1.0]butanes (BCBs) as functionalizable, tunable, and cysteine-selective chiral warheads. The key issues of the paper include: 1. **Developing new warheads**: Synthesizing sulfoximine-containing BCBs from methyl sulfoximine compounds via a one-pot method. These compounds can selectively react with cysteine and remain active under biocompatible conditions. 2. **Enhancing the functionality and diversity of warheads**: Achieving further derivatization of warheads through three vectors (N-modification, aryl BCB-sulfoximine cross-coupling reactions, and metallation and capture of the BCB motif itself), thereby providing a wide range of strain-release reactivity and chemical diversity. 3. **Validating biological application potential**: Demonstrating that these sulfoximine BCBs can selectively label cysteine in protein models (such as CDK2) and preliminarily showcasing their potential in chemical proteomics applications, particularly their chiral labeling capability for cysteine. Through these studies, the paper hopes to provide new tools for protein function research and drug development, especially in the design and screening of covalent inhibitors. These novel warheads can offer higher reactivity and selectivity control, as well as broader functionalization possibilities.